I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors
Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma. Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide
Study Type
OBSERVATIONAL
Enrollment
1,380
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.